Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL31295684 | 0.97 | CA9 (0.46) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL5513421 | 0.93 | CA9 (0.53) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL5511692 | 0.89 | CA9 (0.50) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL19667454 | 0.85 | ADRA2A (0.46) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL29495591 | 0.85 | ADRA2A (0.46) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL3677612 | 0.80 | ESR1 (0.52) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL14783939 | 0.76 | MAPT (0.42) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL6744533 | 0.76 | CA3 (0.40) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL2916768 | 0.76 | CA3 (0.40) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL21614392 | 0.76 | CA3 (0.40) | CA9CA3CA6CA5ACA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119861-A | Preparation method of novel fluorine-containing pyridine type benzoxazine resin friction layer for liquid drop nano generator | 内蒙古大学 | 2024-12-13 | — | — | CN | claimed |
| JP-4831966-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-7622534-B2 | Epoxidation of olefin/diene copolymers using hydrogen peroxide | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-11-24 | — | — | US | claimed |
| WO-2008130435-A2 | EPOXIDATION OF OLEFIN/DIENE COPOLYMERS USING HYDROGEN PEROXIDE | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080132643-A1 | Epoxidation of olefin/diene copolymers using hydrogen peroxide | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-06-05 | — | — | US | claimed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | claimed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | claimed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | claimed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | claimed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| US-5536443-A | DUTERIUM CONTAINING COMPOUNDS FOOR ELECTROOPTICAL APPARATUS | DAINIPPON INK & CHEMICALS, INC. (JP) | 1996-07-16 | — | — | US | disclosed |
| WO-1995009828-A1 | 2,4,5-TRIFLUOROBENZENES AND THEIR USE IN LIQUID CRYSTAL MIXTURES | MERCK PATENT GMBH (DE) | 1995-04-13 | — | — | WO | disclosed |
| US-5081208-A | Using a catalyst system comprising the reaction product of a tungsten compound and a halo- or trihalomethylphenol and a trihydrocarbyltin hydride; RIM; kinetics | SHELL OIL COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0336486-A2 | Polymerization of norbornene derivatives and catalytic system suitable for use therein | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CA9 4868/4885CA3 4874/4885CA6 4623/4885 |
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | CA9 4391/4885CA3 4457/4885CA6 4225/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | CA9 2534/4885CA3 4861/4885CA6 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.